These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18405521)

  • 1. [Risk functions and the primary prevention of cardiovascular disease].
    Grau M; Marrugat J
    Rev Esp Cardiol; 2008 Apr; 61(4):404-16. PubMed ID: 18405521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive assessment of cardiovascular risk: from Framingham to the future.
    Vogel RA; Benitez RM
    Rev Cardiovasc Med; 2000; 1(1):34-42. PubMed ID: 12457150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Estimating cardiovascular risk in Spain using different algorithms].
    Comín E; Solanas P; Cabezas C; Subirana I; Ramos R; Gené-Badía J; Cordón F; Grau M; Cabré-Vila JJ; Marrugat J
    Rev Esp Cardiol; 2007 Jul; 60(7):693-702. PubMed ID: 17663853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment].
    Buitrago F; Cañón-Barroso L; Díaz-Herrera N; Cruces-Muro E; Escobar-Fernández M; Serrano-Arias JM
    Rev Esp Cardiol; 2007 Feb; 60(2):139-47. PubMed ID: 17338879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of coronary risk estimates derived using the Framingham and REGICOR equations].
    Cristóbal J; Lago F; de la Fuente J; González-Juanatey JR; Vázquez-Bellés P; Vila M
    Rev Esp Cardiol; 2005 Aug; 58(8):910-5. PubMed ID: 16053824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular diseases.
    Giampaoli S; Palmieri L; Mattiello A; Panico S
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):79-85. PubMed ID: 15871855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New strategies in cardiovascular prevention].
    Moreno J; Alegría-Barrero E; Cordero A; Fernández-Jarne E; Sáenz de Buruaga JD
    Rev Med Univ Navarra; 2005; 49(3):9-15. PubMed ID: 16400972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cardiovascular risk in primary care patients in France.
    Bruckert E; Bonnelye G; Thomas-Delecourt F; André L; Delaage PH
    Arch Cardiovasc Dis; 2011; 104(6-7):381-7. PubMed ID: 21798470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dyslipidemias and cardiovascular diseases: towards a new perspective].
    Darioli R; Depairon M; Perdrix J; Mooser V
    Rev Med Suisse Romande; 2002 Oct; 122(10):489-93. PubMed ID: 12494781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first SHAPE (Screening for Heart Attack Prevention and Education) guideline.
    Naghavi M; Falk E; Hecht HS; Shah PK;
    Crit Pathw Cardiol; 2006 Dec; 5(4):187-90. PubMed ID: 18340236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of cardiovascular diseases: collaborative program].
    Vértes A; Gyárfás I; Ofner P
    Orv Hetil; 2006 Oct; 147(39):1867-73. PubMed ID: 17111648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular prevention of high risk patients by hypolipidemic treatment].
    Moulin P; Sérusclat A; Bernard S
    Rev Prat; 2005 Oct; 55(16):1783-7. PubMed ID: 16363428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study.
    Devine J; Linton A; Mistry H; Napier J; Trice S; Bacon T
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):891-9. PubMed ID: 19634117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The risk of suffering a cardiovascular disease in the making of decisions. From evidence to the clinic].
    Villar Alvarez F; Maiques Galán A; Franch Taix M; Banegas Banegas JR; Vilaseca Canals J
    Med Clin (Barc); 1999; 112 Suppl 1():67-73. PubMed ID: 10618802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases.
    Hamer M; Chida Y; Stamatakis E
    Am J Cardiol; 2009 Aug; 104(4):538-42. PubMed ID: 19660608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calibrating the SCORE cardiovascular risk chart for use in Spain].
    Sans S; Fitzgerald AP; Royo D; Conroy R; Graham I
    Rev Esp Cardiol; 2007 May; 60(5):476-85. PubMed ID: 17535758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age.
    Scheltens T; Verschuren WM; Boshuizen HC; Hoes AW; Zuithoff NP; Bots ML; Grobbee DE
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):562-6. PubMed ID: 18756178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiovascular risk factors. Insights from Framingham Heart Study].
    O'Donnell CJ; Elosua R
    Rev Esp Cardiol; 2008 Mar; 61(3):299-310. PubMed ID: 18361904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying the vulnerable patient with rupture-prone plaque.
    Weintraub HS
    Am J Cardiol; 2008 Jun; 101(12A):3F-10F. PubMed ID: 18549869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.